Compare Merck & Co., Inc. (MRK) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Revvity Inc — how do they compare? Merck & Co., Inc. trades at $133.61 (market cap $327.94B), while Revvity Inc trades at $118.14 (market cap $13.15B). The key difference: Merck & Co., Inc. is far larger — about 24.9× Revvity Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.56%). Which is the better fit depends on your goals.
| MRK | RVTY | |
|---|---|---|
Market Cap | $327.94B | $13.15B |
Sector | Health | Technology |
52-Week High | $132.93 | $117.88 |
52-Week Low | $77.60 | $82.26 |
Enterprise Value | $374.70B | $15.47B |
Dividend Yield | 2.56% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $133.30, up 2.18% today, with a bullish technical signal and strong institutional buying interest. Recent earnings beats and the acquisition of Terns Pharmaceuticals for $6.7 billion highlight strategic growth in oncology. The stock shows robust cash flow from operations of $16.47 billion in 2025 and a consensus price target of $140.58, indicating potential upside.
Outlook remains positive with analyst consensus at 67.57% buy ratings, though risks include high P/E of 106.34 and net income margin volatility. The acquisition expands Merck's pipeline but integration execution is key. Dividend yield supports income investors, while valuation metrics suggest careful monitoring of earnings growth sustainability.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
